The liposome-based adjuvant system AS01 is under evaluation for use in several vaccines in clinical development. We have shown previously that AS01 injected with hepatitis B surface antigen (HBsAg) induces a distinct cellular signature within the draining lymphatics that enhances local lymphocyte recruitment and antigen-specific humoral immunity. Here, we show that AS01-induced neutrophil recruitment is associated with increased expression of CD14 and enhanced antigen uptake capacity in neutrophils from both afferent and efferent lymphatic compartments during the first 48 h after vaccination. Significant and transient increases in CD14 expression on systemic neutrophils were also observed following primary and boost vaccination with HBsAg-AS01; however, they were not observed following additional encounter with HBsAg-alone or HBsAg-alum. These results show that following immunization with AS01, neutrophils expressing higher levels of CD14 are both more abundant and efficient at antigen uptake, warranting further investigation into the role of neutrophilassociated CD14 in the adjuvanticity of AS01.
Introduction
Neutrophils, the most abundant immune cell population in human blood, are critical in the non-specific control of infection and the induction of inflammatory immune responses [1] . Recent evidence has revealed that neutrophils are also involved in the activation and regulation of adaptive immune responses [2, 3] . The liposome-based adjuvant system AS01 incorporates two immune stimulants, 3-O-desacyl-4 0 -monophosphoryl lipid A (MPL) and the saponin QS-21. AS01 is used in the malarial vaccine RTS,S/AS01 and is under investigation for use in several candidate vaccines, including those targeting HIV, herpes zoster and tuberculosis [4] [5] [6] [7] [8] [9] . It was recently shown that AS01 drives adaptive immunity via innate immune cell activation and enhancement of dendritic cell antigen presentation in the local draining lymph node [10] .
The early immune response to vaccination is characterized by the translocation of activated innate cells from the injection site to the local lymph node via the afferent lymphatic vessels. Following interaction of these peripheral innate cells with lymphocytes in the lymph node, antigenspecific lymphocytes leave the lymph node via the efferent lymphatics, where they eventually drain back into the circulation and perform their required effector function [11] . Surgical cannulation of the afferent and efferent lymphatic vessels during the innate and adaptive phases of an immune response to vaccination reveals the real-time in-vivo cellular response induced by a vaccine formulation.
Using this surgical model, we recently reported that AS01 injected with hepatitis B surface antigen (HBsAg) induces a distinct and transient innate cellular signature within the draining lymphatics that enhances local lymphocyte recruitment and systemic antigen-specific humoral immunity [12] . We reported that immediately upon HBsAg-AS01 injection, most antigen is found in neutrophils, whose number increases transiently in the lymphatic compartment draining the site of injection. Here, we have directly cannulated afferent and efferent lymphatic vessels draining the prefemoral injection site to perform a detailed analysis of this neutrophil response. We report an increase in CD14 expression on lymphatic neutrophils following vaccination with AS01 that correlates directly with increased neutrophil-associated antigen uptake capacity.
Significant and transient increases in CD14 expression on systemic neutrophils were also observed following primary and boost vaccination with HBsAg-AS01; however, they were not observed following additional encounter with HBsAg-alone or HBsAg-alum. This study reveals a potential role for local and systemic neutrophils in the in-vivo immune response induced by the adjuvant AS01.
Materials and methods

Vaccine formulations
AS01 and the hepatitis B surface antigen (HBsAg) were obtained from GSK Vaccines (Rixensart, Belgium). HBsAg was produced from genetically engineered yeast (Saccharomyces cerevisiae) and was formulated in AS01, an adjuvant system containing QS-21 (Quillaja saponaria Molina, fraction 21; licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation) and MPL (GSK Vaccines) in a liposome-based formulation, as described previously [10] . For antigen labelling, HBsAg was resuspended at 1 mg/ml in phosphate-buffered saline (PBS) and a 15 M excess of A647 succinimidyl ester (Invitrogen, Carlsbad, CA, USA) resuspended in dimethylsulphoxide (DMSO) at 5 mg/ml was added and incubated at room temperature for 1 h. Unconjugated fluorophore was removed from solution using an Amicon Ultracel 3K centrifugal filter (Millipore, Burlington, MA, USA) by centrifuging at 2000 g for 30 min and washed with PBS five times. We injected 500 ml of AS01-HBs, the equivalent of a standard adult human dose of AS01 comprising 50 mg MPL and 50 mg QS-21 in a liposome-based formulation with 40 mg of antigen (35 mg HBsAg 1 5 mg A647-HBsAg). Injections were performed with a 25G needle subcutaneously in the area drained by the prefemoral lymph node.
Immunization strategy
For afferent lymph experiments, four animals that had received prefemoral pseudoafferent lymphatic cannulation surgery received a single subcutaneous (s.c.). injection of HBsAg-AS01. For efferent lymph experiments, five animals that had received prefemoral efferent lymphatic cannulation surgery received a single s.c. injection of AS01. For blood experiments, a separate cohort of 11 animals that had not received any surgery were assigned randomly to receive primary and secondary injections with HBsAg-AS01 s.c. (n 5 6) or HBsAg-AS01 intramuscularly (i.m.) (n 5 5). Animals that received two injections of HBsAg-AS01 s.c. received a third injection of HBsAg s.c. formulated with alum and animals that received two injections of HBsAg-AS01 i.m. received a third injection of HBsAg i.m. in saline. In a control experiment (Supporting information, Fig. S1 ) to determine if the effects observed with AS01 in the circulation were also induced by primary and secondary vaccination with HBsAg formulated with alum, a separate cohort of four animals that had not received any surgery received primary and secondary injections with HBsAg-alum i.m. For all blood experiments, secondary injections were performed 4 weeks following primary injection, and tertiary injections were performed 7 days following secondary injection.
Pseudoafferent and efferent prefemoral lymphatic cannulation surgery
Ovine prefemoral pseudoafferent and efferent lymphatic cannulations were performed as described previously [13] . Briefly, for prefemoral pseudoafferent lymphatic cannulation, the prefemoral lymph nodes of merino sheep were removed at 1 year of age and at least 2 months was allowed for re-anastomosis of the afferent lymphatics with the larger efferent lymphatic vessel. A secondary surgery was performed to insert a 0Á96 3 0Á58 mm heparin-coated polyurethane cannula into the pseudoafferent lymphatic vessel. For prefemoral and iliac efferent lymphatic cannulation, a 0Á96 3 0Á58 mm heparin-coated polyurethane cannula was inserted into the efferent lymphatic vessel of the prefemoral lymph node and a 1Á65 3 0Á58 mm heparincoated polyurethane cannula was inserted into the efferent lymphatic vessel of the iliac lymph node. For both cannulation models, the cannulae were exteriorized and placed in a sterile collection flask attached to the side of the sheep. Injections were given at least 7 days post-lymphatic surgery to allow for surgical recovery. All sheep were obtained from a Monash University approved supplier and written approval for all animal experiments was obtained from the Monash University Ethics Committee (approval number: MARP/2013/054). Animals were maintained and cared for in purpose-built facilities. Food and water were available ad libitum at all times, excluding the 18 h prior to surgery.
Sample collection, flow cytometry and cell sorting
Prefemoral afferent and prefemoral and iliac efferent lymph was collected on ice in sterile 50 ml tubes containing 0Á05 IU of heparin (Pfizer, New York, NY, USA) and 20 ml of 3100 cell culture penicillin-streptomycin (Invitrogen) for no longer than 1 h before the ice was refreshed. Afferent and efferent lymph was collected prior to primary injection, 0-4, 4-8, 8-12, 16-24, 24-28, 28-30, 48-50 and 72-73 h post-injection. Afferent and efferent lymph cells were prepared for flow cytometry as reported previously [12] . Heparanized blood was collected by venepuncture from the jugular vein. Immediately after collection, 100 ml of whole blood was lysed and treated as described previously for flow cytometry analysis [12] .
The surface marker antibodies used were anti-major histocompatibility complex ( Fig. 3a and Fig. 4a and are consistent with our previous work [12, 14] . Pre-vaccination levels of CD14 were used to determine the cut-off for CD14 low and CD14 high neutrophil populations; were any CD14 expression greater than pre-vaccination, CD14 level was determined as the CD14 high population. Samples for cell sorting were prepared in the same manner as for flow cytometry analysis. Neutrophils from blood 24 h post-AS01 injection were fluorescence-activated cell sorted (FACS) using a BD Influx cell sorter. Following cell sorting, 1 3 10 5 sorted neutrophils were centrifuged onto glass slides using a cytospot centrifuge (120 g for 5 min at 48C) and stained with DiffQuik.
Statistical analysis
Results are presented as mean 6 standard error of the mean. Differences between groups and within each group were calculated with a one-or two-way repeated-measures (RM) analysis of variance (ANOVA) using a Holm-Sidak post-test to correct for multiple comparisons. Significance was determined as the confidence interval being greater than 95% (P < 0Á05). The statistical software used was GraphPad Prism version 6.01.
Results
HBsAg-AS01 induces CD14
high neutrophils in afferent lymph that carry more antigen to the draining lymph node compared to CD14 low neutrophils
We have shown previously that neutrophils enter the afferent lymphatics rapidly following vaccination with a range of adjuvants, and are responsible for the majority of cell-associated antigen transport within the first 24 h of vaccination [13] [14] [15] [16] . Here, we confirm that HBsAg-AS01 induced the rapid recruitment of neutrophils into afferent lymph within 4 h after subcutaneous injection. This initial inflammatory response returned to baseline after 30 h (Fig.  1a) . While peak neutrophil migration in afferent lymph occurred between 4 and 8 h, an increase in the percentage of CD14 high neutrophils and MFI of CD14 on the surface of neutrophils occurred 16-24 h after injection (Fig. 1b-e) . The CD14 high neutrophils were more efficient than CD14 low neutrophils at transporting HBsAg throughout the vaccination time-course. This effect is observed when expressed as percentage of neutrophils carrying antigen and also as HBsAg mean fluorescence intensity (MFI) (Fig. 1e-g ). No change in expression of other markers on afferent lymph neutrophils was observed following injection with HBsAg-AS01, including isotype control, CD16, MHC-II and SIRPa (CD172) (data not shown).
CD14
high neutrophils migrate out of the lymph node via efferent lymph following vaccination with HBsAg-AS01 Neutrophils comprised between 2 and 3% of cells leaving the lymph node via efferent lymph between 4 and 30 h after vaccination with HBsAg-AS01 (Fig. 2a) . Similar to afferent lymph, an increase in the percentage of CD14 high neutrophils in efferent lymph was observed from 16 to 30 h after vaccination (Fig. 2b-d ). While no difference in the percentage of HBsAg-positive cells was observed between the neutrophil subsets, the CD14 high neutrophils demonstrated significantly greater HBsAg MFI 24-30 h after vaccination with HBsAg-AS01 when compared to CD14 low neutrophils ( Fig. 2e-g ). A similar pattern of CD14 expression was observed in muscle efferent lymph following i.m. vaccination (Supporting information, Fig. S2 ). Unlike HBsAg-AS01, vaccination with HBsAg-alum did not induce neutrophil emigration from the lymph node (data not shown).
CD14 expression is transiently increased on peripheral blood neutrophils following primary and secondary vaccination with HBsAg-AS01
We have previously reported a significant 2Á2-and 1Á6-fold increase in the percentage of neutrophils observed in peripheral blood 24 h following primary and secondary vaccination with HBsAg-AS01, respectively, which returned to baseline during the following 3-5 days [12] . Here, we show that the increase in systemic neutrophils is not observed following injection with HBsAg-alum (Supporting information, Fig. S1 ). A dramatic increase in the percentage of peripheral blood CD14 high neutrophils was also observed 24 h following vaccination with HBsAg-AS01, with an average 8Á9-fold increase in the percentage of CD14 high neutrophils observed 24 h following primary vaccination and a 10Á4-fold increase in the percentage of CD14 high neutrophils observed 24 h following secondary vaccination ( Fig. 3b-d (Fig. 3e) .
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Recall injection with HBsAg in the absence of AS01 did not recapitulate the neutrophil-associated response
To determine if the observed neutrophil response can be elicited with antigen alone and/or previous HBsAg-AS01 immunization induces a memory response that could be recapitulated upon re-encounter with antigen alone, sheep previously injected twice with HBsAg-AS01 received a third injection of HBsAg-alum or HBsAg-saline. Neither
HBsAg-alum nor HBsAg-saline increased the percentage of blood neutrophils or induced the expression of CD14 on neutrophils at any time-point after vaccination (Fig. 4b-d ).
Discussion
Neutrophils have long been known to play a crucial role in the immediate inflammatory response and clearance of pathogens. Recent evidence has revealed that neutrophils are also involved in the activation and regulation of adaptive immune responses [2] . Indeed, neutrophils from human blood have been shown to express specific transcriptional repertories under different inflammatory conditions [17] , suggesting that these cells may not only play a role in non-specific inflammation but may be also involved in a more tailored immune response. The depletion or inactivation of neutrophils in mice increases the immune response within distal lymph nodes in a thromboxane A2-dependent manner [18] , suggesting that neutrophils play a key role in limiting the spread of immune cell trafficking.
We have shown previously that neutrophils enter the afferent lymphatics rapidly following vaccination with a range of innate stimulating adjuvants and are responsible for the majority of cell-associated antigen transport within the first 24 h of vaccination [13] [14] [15] [16] . The current study shows that vaccination with HBsAg formulated with AS01 induces the up-regulation of CD14 on local and systemic neutrophils. This was not observed following vaccination with HBsAg-alum nor in previous studies after injection of the innate adjuvants poly(I:C) or cytosine-phosphate-guanosine (CpG) [13, 14] . This 
CD14
high neutrophils (red) and HBsAg 1 CD14 low neutrophils (blue) overlayed onto a background of all neutrophils in EL (grey) at each timepoint. Antigen uptake in each neutrophil subset is also quantified as (f) percentage and (g) HBsAg-A647 MFI over the vaccination time-course. A repeated-measures one-or two-way analysis of variance (ANOVA) with a Holm-Sidak multiple comparisons test was used to determine significance, where * indicates differences between groups and # indicates differences from baseline (pre) within each group, *P < 0Á05, **P < 0Á01, #P < 0Á05, ##P < 0Á01. [Colour figure can be viewed at wileyonlinelibrary.com]
suggests a unique effect of AS01, a liposomal adjuvant system including the saponin QS-21 and the Toll-like receptor (TLR)-4 ligand MPL. Interestingly, MPL is a modified derivative of LPS and its biological activity is dependent upon TLR-4 and CD14 expression on innate cells [19] . Given that neutrophils have been shown to express TLR-4 [20] , this raises the possibility that MPL directly activates neutrophils via TLR-4, which may result in increased CD14 expression. This provides further evidence that CD14 high neutrophils may have enhanced functional capacity when migrating to and from the local lymph node after vaccination with HBsAg-AS01. It is therefore clear from our own and other studies that AS01 induces a transient inflammatory response at the site of injection and in the circulation [10, 21] . However, of equal importance is the transient nature of this response, which resolves within 30 h in the lymphatic network and within 48 h in peripheral blood. Even following secondary vaccination with AS01, the systemic inflammatory response resolves after 72 h. While extended systemic inflammation may lead to enhanced vaccine reactogenicity, it may also enhance immunity. Our previous studies have confirmed that AS01 is an effective adjuvant with no evidence of localized or systemic vaccine side effects, including site reactions, fever, lethargy or reduced food intake [12] .
The increase in CD14 expression on neutrophils in peripheral blood is not induced following tertiary injection with antigen alone or antigen injected with aluminium adjuvant, suggesting that the response is induced specifically by AS01 as part of the innate response, and not remembered following additional encounter with antigen. Combined with the observation that CD14 high neutrophils are responsible for increased antigen transport to and from the local lymph node in the immediate hours following 
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